Doxycycline Capsules Recalled Due to Temperature Storage Deviation
Cardinal Healthcare is recalling Doxycycline 100 mg Capsules nationwide due to exposure to temperatures outside labeled storage conditions. No illnesses have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall without reported illnesses or injuries. The hazard is a manufacturing deviation—temperature exposure—that could affect drug stability and efficacy, but no confirmed harm has been reported.
Plain-English summary
Cardinal Healthcare is recalling Doxycycline Capsules, USP 100 mg, Batch G104819, due to manufacturing deviations. The product was manufactured by Lupin Limited in Nagpur, India for Lupin Pharmaceuticals, Inc.
The recall was issued because products were exposed to temperatures outside the labeled storage conditions. Temperature excursions can potentially affect the stability and efficacy of the antibiotic medication.
This recall affects Doxycycline 100 mg capsules with Batch G104819 distributed nationwide. The affected product is identified by NDC numbers 68180-650, 68180-651, and 68180-652.
The recalled product
- Product
- DOXYCYCLINE (DOXYCYCLINE)
- Brand
- DOXYCYCLINE
- Manufacturer
- CARDINAL HEALTHCARE
- Category
- Drug
- Hazard
- temperature-excursion
- storage-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Batch G104819
UPCs (2)
- 0368180652083
- 0368180650010
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DOXYCYCLINE
- HighDoxycycline antibiotic tablets recalled for failed dissolution specifications
FDA (Drugs) · 2025-10-15
- ModerateDoxycycline Capsules Recalled for Temperature Control Deviation
FDA (Drugs) · 2022-06-15
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27